PMID- 33777821
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 2235-0640 (Print)
IS  - 2235-0802 (Electronic)
IS  - 2235-0640 (Linking)
VI  - 10
IP  - 1
DP  - 2021 Mar
TI  - Quality of Life during Treatment with Lenvatinib for Thyroid Cancer: The 
      Patients' Perspective beyond the Medical Evaluation.
PG  - 65-71
LID - 10.1159/000508186 [doi]
AB  - BACKGROUND: Lenvatinib (LEN) has shown great efficacy but important toxicity in 
      patients with advanced radioactive iodine-refractory (RAI-R) thyroid cancer (TC); 
      a focused evaluation of its impact on patients' quality of life (QoL) is still 
      lacking. Our prospective study investigated the impact of this drug on QoL in a 
      group of RAI-R TC patients treated at our centre. METHODS: All patients filled in 
      two questionnaires before and during treatment: (1) the Patient-Reported Outcomes 
      version of the Common Terminology Criteria for Adverse Events adapted 
      questionnaire, assessing prevalence, severity, and/or interference on daily 
      activities of the most frequent symptomatic adverse events (AEs) reported in 
      previous clinical trials during therapy with LEN, and (2) the European Quality of 
      Life 5 Dimensions 3 Levels (EQ-5D-3L) questionnaire, providing the EQ-5D index 
      and the EQ visual analogue scale (EQ-VAS). Data from baseline questionnaires were 
      compared with those obtained 3, 6, and 12 months after the start of treatment. 
      RESULTS: In our population (n = 20), an overall increased perception of 
      symptomatic AEs emerged during treatment (statistically significant for abdominal 
      pain, asthenia/fatigue, decreased appetite, and xerostomia). The median EQ-5D 
      index and EQ-VAS scores after 3 months of treatment were lower than at baseline, 
      almost returning to initial values after 12 months. CONCLUSION: RAI-R TC patients 
      reported a general increase in prevalence and interference on daily activities of 
      symptomatic AEs during therapy with LEN. Self-perceived QoL initially decreased 
      during therapy. However, our data suggest that QoL could be restored after 12 
      months; this trend might partly reflect the impact of therapy optimisation.
CI  - Copyright (c) 2020 by European Thyroid Association Published by S. Karger AG, 
      Basel.
FAU - Nervo, Alice
AU  - Nervo A
AD  - Oncological Endocrinology Unit, Department of Medical Sciences, University of 
      Turin, Citta della Salute e della Scienza Hospital, Turin, Italy.
FAU - Ragni, Alberto
AU  - Ragni A
AD  - Oncological Endocrinology Unit, Department of Medical Sciences, University of 
      Turin, Citta della Salute e della Scienza Hospital, Turin, Italy.
FAU - Piovesan, Alessandro
AU  - Piovesan A
AD  - Oncological Endocrinology Unit, Department of Medical Sciences, University of 
      Turin, Citta della Salute e della Scienza Hospital, Turin, Italy.
FAU - Marica, Valentina
AU  - Marica V
AD  - Oncological Endocrinology Unit, Department of Medical Sciences, University of 
      Turin, Citta della Salute e della Scienza Hospital, Turin, Italy.
FAU - Migliore, Enrica
AU  - Migliore E
AD  - Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, 
      Citta della Salute e della Scienza Hospital, Turin, Italy.
FAU - Gallo, Marco
AU  - Gallo M
AD  - Oncological Endocrinology Unit, Department of Medical Sciences, University of 
      Turin, Citta della Salute e della Scienza Hospital, Turin, Italy.
FAU - Arvat, Emanuela
AU  - Arvat E
AD  - Oncological Endocrinology Unit, Department of Medical Sciences, University of 
      Turin, Citta della Salute e della Scienza Hospital, Turin, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200713
PL  - England
TA  - Eur Thyroid J
JT  - European thyroid journal
JID - 101604579
PMC - PMC7983562
OTO - NOTNLM
OT  - Health-related quality of life
OT  - Patient-reported outcome
OT  - Thyroid cancer
OT  - Tyrosine kinase inhibitors
COIS- There is no conflict of interest that could be perceived as prejudicing the 
      impartiality of the research reported.
EDAT- 2021/03/30 06:00
MHDA- 2021/03/30 06:01
PMCR- 2021/09/01
CRDT- 2021/03/29 06:35
PHST- 2020/03/13 00:00 [received]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2021/03/29 06:35 [entrez]
PHST- 2021/03/30 06:00 [pubmed]
PHST- 2021/03/30 06:01 [medline]
PHST- 2021/09/01 00:00 [pmc-release]
AID - etj-0010-0065 [pii]
AID - 10.1159/000508186 [doi]
PST - ppublish
SO  - Eur Thyroid J. 2021 Mar;10(1):65-71. doi: 10.1159/000508186. Epub 2020 Jul 13.